Incyte signs AI deals with Genesis Molecular AI, Edison Scientific

Summary

Incyte has signed AI partnerships with Genesis Molecular AI and Edison Scientific to leverage artificial intelligence in drug development. The 35-year-old Delaware-based biopharma company, valued at $19 billion, is integrating AI technology to support its future pipeline.